Role of cMET in the development and progression of colorectal cancer

Juan Carlos Samamé Pérez-Vargas, Pamela Biondani, Claudia Maggi, Manuela Gariboldi, Annunziata Gloghini, Alessandro Inno, Chiara Costanza Volpi, Ambra Vittoria Gualeni, Maria di Bartolomeo, Filippo de Braud, Alessandra Castano, Ilaria Bossi, Filippo Pietrantonio

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Mesenchymal-epithelial transition (MET) is a member of a distinct subfamily of heterodimeric receptor tyrosine kinase receptors that specifically binds the hepatocyte growth factor (HGF). Binding to HGF leads to receptor dimerization/multimerization and phosphorylation, resulting in its catalytic activation. MET activation drives the malignant progression of several tumor types, including colorectal cancer (CRC), by promoting signaling cascades that mainly result in alterations of cell motility, survival, and proliferation. MET is aberrantly activated in many human cancers through various mechanisms, including point mutations, gene amplification, transcriptional up-regulation, or ligand autocrine loops. MET promotes cell scattering, invasion, and protection from apoptosis, thereby acting as an adjuvant pro-metastatic gene for many tumor types. In CRC, MET expression confers more aggressiveness and worse clinical prognosis. With all of this rationale, inhibitors that target the HGF/MET axis with different types of response have been developed. HGF and MET are new promising targets to understand the pathogenesis of CRC and for the development of new, targeted therapies.

Original languageEnglish
Pages (from-to)18056-18077
Number of pages22
JournalInternational Journal of Molecular Sciences
Volume14
Issue number9
DOIs
Publication statusPublished - Sep 3 2013

Fingerprint

Epithelial-Mesenchymal Transition
Hepatocyte Growth Factor
progressions
Colorectal Neoplasms
cancer
Tumors
Chemical activation
Phosphorylation
Dimerization
Receptor Protein-Tyrosine Kinases
genes
Cell death
tumors
activation
Genes
Ligands
pathogenesis
Neoplasms
Scattering
phosphorylation

Keywords

  • Colorectal cancer
  • Hepatocyte growth factor
  • Mesenchymal-epithelial transition factor
  • Pathogenesis
  • Prognosis

ASJC Scopus subject areas

  • Computer Science Applications
  • Molecular Biology
  • Catalysis
  • Inorganic Chemistry
  • Spectroscopy
  • Organic Chemistry
  • Physical and Theoretical Chemistry

Cite this

Role of cMET in the development and progression of colorectal cancer. / Pérez-Vargas, Juan Carlos Samamé; Biondani, Pamela; Maggi, Claudia; Gariboldi, Manuela; Gloghini, Annunziata; Inno, Alessandro; Volpi, Chiara Costanza; Gualeni, Ambra Vittoria; di Bartolomeo, Maria; de Braud, Filippo; Castano, Alessandra; Bossi, Ilaria; Pietrantonio, Filippo.

In: International Journal of Molecular Sciences, Vol. 14, No. 9, 03.09.2013, p. 18056-18077.

Research output: Contribution to journalArticle

Pérez-Vargas, JCS, Biondani, P, Maggi, C, Gariboldi, M, Gloghini, A, Inno, A, Volpi, CC, Gualeni, AV, di Bartolomeo, M, de Braud, F, Castano, A, Bossi, I & Pietrantonio, F 2013, 'Role of cMET in the development and progression of colorectal cancer', International Journal of Molecular Sciences, vol. 14, no. 9, pp. 18056-18077. https://doi.org/10.3390/ijms140918056
Pérez-Vargas, Juan Carlos Samamé ; Biondani, Pamela ; Maggi, Claudia ; Gariboldi, Manuela ; Gloghini, Annunziata ; Inno, Alessandro ; Volpi, Chiara Costanza ; Gualeni, Ambra Vittoria ; di Bartolomeo, Maria ; de Braud, Filippo ; Castano, Alessandra ; Bossi, Ilaria ; Pietrantonio, Filippo. / Role of cMET in the development and progression of colorectal cancer. In: International Journal of Molecular Sciences. 2013 ; Vol. 14, No. 9. pp. 18056-18077.
@article{45db814d51bf4d3181a172edadc5903a,
title = "Role of cMET in the development and progression of colorectal cancer",
abstract = "Mesenchymal-epithelial transition (MET) is a member of a distinct subfamily of heterodimeric receptor tyrosine kinase receptors that specifically binds the hepatocyte growth factor (HGF). Binding to HGF leads to receptor dimerization/multimerization and phosphorylation, resulting in its catalytic activation. MET activation drives the malignant progression of several tumor types, including colorectal cancer (CRC), by promoting signaling cascades that mainly result in alterations of cell motility, survival, and proliferation. MET is aberrantly activated in many human cancers through various mechanisms, including point mutations, gene amplification, transcriptional up-regulation, or ligand autocrine loops. MET promotes cell scattering, invasion, and protection from apoptosis, thereby acting as an adjuvant pro-metastatic gene for many tumor types. In CRC, MET expression confers more aggressiveness and worse clinical prognosis. With all of this rationale, inhibitors that target the HGF/MET axis with different types of response have been developed. HGF and MET are new promising targets to understand the pathogenesis of CRC and for the development of new, targeted therapies.",
keywords = "Colorectal cancer, Hepatocyte growth factor, Mesenchymal-epithelial transition factor, Pathogenesis, Prognosis",
author = "P{\'e}rez-Vargas, {Juan Carlos Samam{\'e}} and Pamela Biondani and Claudia Maggi and Manuela Gariboldi and Annunziata Gloghini and Alessandro Inno and Volpi, {Chiara Costanza} and Gualeni, {Ambra Vittoria} and {di Bartolomeo}, Maria and {de Braud}, Filippo and Alessandra Castano and Ilaria Bossi and Filippo Pietrantonio",
year = "2013",
month = "9",
day = "3",
doi = "10.3390/ijms140918056",
language = "English",
volume = "14",
pages = "18056--18077",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "9",

}

TY - JOUR

T1 - Role of cMET in the development and progression of colorectal cancer

AU - Pérez-Vargas, Juan Carlos Samamé

AU - Biondani, Pamela

AU - Maggi, Claudia

AU - Gariboldi, Manuela

AU - Gloghini, Annunziata

AU - Inno, Alessandro

AU - Volpi, Chiara Costanza

AU - Gualeni, Ambra Vittoria

AU - di Bartolomeo, Maria

AU - de Braud, Filippo

AU - Castano, Alessandra

AU - Bossi, Ilaria

AU - Pietrantonio, Filippo

PY - 2013/9/3

Y1 - 2013/9/3

N2 - Mesenchymal-epithelial transition (MET) is a member of a distinct subfamily of heterodimeric receptor tyrosine kinase receptors that specifically binds the hepatocyte growth factor (HGF). Binding to HGF leads to receptor dimerization/multimerization and phosphorylation, resulting in its catalytic activation. MET activation drives the malignant progression of several tumor types, including colorectal cancer (CRC), by promoting signaling cascades that mainly result in alterations of cell motility, survival, and proliferation. MET is aberrantly activated in many human cancers through various mechanisms, including point mutations, gene amplification, transcriptional up-regulation, or ligand autocrine loops. MET promotes cell scattering, invasion, and protection from apoptosis, thereby acting as an adjuvant pro-metastatic gene for many tumor types. In CRC, MET expression confers more aggressiveness and worse clinical prognosis. With all of this rationale, inhibitors that target the HGF/MET axis with different types of response have been developed. HGF and MET are new promising targets to understand the pathogenesis of CRC and for the development of new, targeted therapies.

AB - Mesenchymal-epithelial transition (MET) is a member of a distinct subfamily of heterodimeric receptor tyrosine kinase receptors that specifically binds the hepatocyte growth factor (HGF). Binding to HGF leads to receptor dimerization/multimerization and phosphorylation, resulting in its catalytic activation. MET activation drives the malignant progression of several tumor types, including colorectal cancer (CRC), by promoting signaling cascades that mainly result in alterations of cell motility, survival, and proliferation. MET is aberrantly activated in many human cancers through various mechanisms, including point mutations, gene amplification, transcriptional up-regulation, or ligand autocrine loops. MET promotes cell scattering, invasion, and protection from apoptosis, thereby acting as an adjuvant pro-metastatic gene for many tumor types. In CRC, MET expression confers more aggressiveness and worse clinical prognosis. With all of this rationale, inhibitors that target the HGF/MET axis with different types of response have been developed. HGF and MET are new promising targets to understand the pathogenesis of CRC and for the development of new, targeted therapies.

KW - Colorectal cancer

KW - Hepatocyte growth factor

KW - Mesenchymal-epithelial transition factor

KW - Pathogenesis

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84883636808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883636808&partnerID=8YFLogxK

U2 - 10.3390/ijms140918056

DO - 10.3390/ijms140918056

M3 - Article

C2 - 24005867

AN - SCOPUS:84883636808

VL - 14

SP - 18056

EP - 18077

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 9

ER -